ArticleAmerican journal of hematology2009
Balancing role of nitric oxide in complement-mediated activation of platelets from mCd59a and mCd59b double-knockout mice.
Article in American journal of hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Enhanced complement activation and MAC formation accelerates severe COVID-19.Cellular and molecular life sciences : CMLS · 2024Article
- Emerging role of complement in COVID-19 and other respiratory virus diseases.Cellular and molecular life sciences : CMLS · 2024Review
- The NO Answer for Autism Spectrum Disorder.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Complement and complement regulatory proteins are upregulated in lungs of COVID-19 patients.Pathology, research and practice · 2023Article
- Regulation of Complement Activation by Heme Oxygenase-1 (HO-1) in Kidney Injury.Antioxidants (Basel, Switzerland) · 2021Review
- Endothelial cell infection and dysfunction, immune activation in severe COVID-19.Theranostics · 2021Article
- Novel insights into the treatment of complement-mediated hemolytic anemias.Therapeutic advances in hematology · 2019Review
- Proteinase 3 expression on the neutrophils of patients with paroxysmal nocturnal hemoglobinuria.Experimental and therapeutic medicine · 2018Article
- Review
- Role of complement and complement regulatory proteins in the complications of diabetes.Endocrine reviews · 2015Review
- Vasculopathy and pulmonary hypertension in sickle cell disease.American journal of physiology. Lung cellular and molecular physiology · 2015Review
- The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe.Haematologica · 2013Article
- Updated role of nitric oxide in disorders of erythrocyte function.Cardiovascular & hematological disorders drug targets · 2013Review
- A novel hemoglobin-binding peptide reduces cell-free hemoglobin in murine hemolytic anemia.American journal of physiology. Heart and circulatory physiology · 2013Article
- Cell surface complement regulators moderate experimental myasthenia gravis pathology.Muscle & nerve · 2013Article
- A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
CD59 is a membrane protein inhibitor of the membrane attack complex (MAC) of complement. mCd59 knockout mice reportedly exhibit hemolytic anemia and platelet activation. This phenotype is comparable to the human hemolytic anemia known as paroxysmal nocturnal hemoglobinuria (PNH), in which platelet activation and thrombosis play a critical pathogenic role. It has long been suspected but not formally demonstrated that both complement and nitric oxide (NO) contribute to PNH thrombosis. Using mCd59a and mCd59b double knockout mice (mCd59ab(-/-) mice) in complement sufficient (C3(+/+)) and deficient (C3(-/-)) backgrounds, we document that mCd59ab(-/-) platelets are sensitive to complement-mediated activation and provide evidence for possible in vivo platelet activation in mCd59ab(-/-) mice. Using a combination of L-NAME (a NO-synthase inhibitor) and NOC-18 or SNAP (NO-donors), we further demonstrate that NO regulates complement-mediated activation of platelets. These results indicate that the thrombotic diathesis of PNH patients could be due to a combination of increased complement-mediated platelet activation and reduced NO-bioavailability as a consequence of hemolysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.